1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchmidt, Marion-
dc.contributor.authorBrunner, Beatrice-
dc.contributor.authorWieser, Simon-
dc.contributor.authorRapold, Roland-
dc.contributor.authorBlozik, Eva-
dc.date.accessioned2022-12-20T13:24:28Z-
dc.date.available2022-12-20T13:24:28Z-
dc.date.issued2018-
dc.identifier.issn0903-1936de_CH
dc.identifier.issn1399-3003de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/26471-
dc.description.abstractBackground: Asthma and COPD are chronic respiratory diseases with substantial burden. Only appropriate treatment and disease management can reduce symptoms and treatment costs. Such evidence is sparse though, especially in Switzerland. Objective: To assess the costs of asthma and COPD by severity according to GINA and GOLD treatment guidelines in Switzerland. Methods: We used 2016 Swiss health insurance data. Patients were identified as asthma and COPD patients if they had received at least one drug of the R03 group in the ATC drug classification. Differentiation between asthma and COPD patients was carried out in two steps: First, patients were directly assigned to one or the other disease based on disease specific drugs, inpatient diagnoses, age, medical examinations and devices. Second, a statistical model was developed to classify patients that could not be classified in the first step. Disease severity was assessed based on medication. GINA and GOLD treatment steps served as proxy for disease severity. Results: Prevalence of treated asthma was estimated at 5.1% to 6.4% and at 2.6% to 4.5% for COPD in patients over the age of 30. Directs medical costs were estimated at 137m to 175m Euro for asthma and at 165m to 204m Euro for COPD. Indirect costs were estimated at 217m to 280m Euro for asthma and 204m to 677m Euro for COPD. Costs were increasing with severity for both diseases. Conclusions: This is the first study using Swiss health insurance data in this context. Such data are highly valuable because of their high accuracy. Evidence on severity distribution and corresponding costs may help identify weaknesses in treatment and reduce costs by attaining better disease control.de_CH
dc.language.isoende_CH
dc.publisherEuropean Respiratory Societyde_CH
dc.relation.ispartofEuropean Respiratory Journalde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectAsthmade_CH
dc.subjectCOPDde_CH
dc.subjectRespiratory diseasede_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleAssessing epidemiology and costs of asthma and COPD in Switzerland with health insurance datade_CH
dc.typeKonferenz: Sonstigesde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
dc.identifier.doi10.1183/13993003.congress-2018.PA3150de_CH
zhaw.conference.detailsERS International Congress, Paris, France, 15-19 September 2018de_CH
zhaw.funding.euNode_CH
zhaw.issueSuppl 62de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.startPA3150de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume52de_CH
zhaw.publication.reviewPeer review (Abstract)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Schmidt, M., Brunner, B., Wieser, S., Rapold, R., & Blozik, E. (2018). Assessing epidemiology and costs of asthma and COPD in Switzerland with health insurance data [Conference presentation]. European Respiratory Journal, 52(Suppl 62), PA3150. https://doi.org/10.1183/13993003.congress-2018.PA3150
Schmidt, M. et al. (2018) ‘Assessing epidemiology and costs of asthma and COPD in Switzerland with health insurance data’, in European Respiratory Journal. European Respiratory Society, p. PA3150. Available at: https://doi.org/10.1183/13993003.congress-2018.PA3150.
M. Schmidt, B. Brunner, S. Wieser, R. Rapold, and E. Blozik, “Assessing epidemiology and costs of asthma and COPD in Switzerland with health insurance data,” in European Respiratory Journal, 2018, vol. 52, no. Suppl 62, p. PA3150. doi: 10.1183/13993003.congress-2018.PA3150.
SCHMIDT, Marion, Beatrice BRUNNER, Simon WIESER, Roland RAPOLD und Eva BLOZIK, 2018. Assessing epidemiology and costs of asthma and COPD in Switzerland with health insurance data. In: European Respiratory Journal. Conference presentation. European Respiratory Society. 2018. S. PA3150
Schmidt, Marion, Beatrice Brunner, Simon Wieser, Roland Rapold, and Eva Blozik. 2018. “Assessing Epidemiology and Costs of Asthma and COPD in Switzerland with Health Insurance Data.” Conference presentation. In European Respiratory Journal, 52:PA3150. European Respiratory Society. https://doi.org/10.1183/13993003.congress-2018.PA3150.
Schmidt, Marion, et al. “Assessing Epidemiology and Costs of Asthma and COPD in Switzerland with Health Insurance Data.” European Respiratory Journal, vol. 52, no. Suppl 62, European Respiratory Society, 2018, p. PA3150, https://doi.org/10.1183/13993003.congress-2018.PA3150.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.